NCT01202890 2014-01-08Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian CancerNew Mexico Cancer Research AlliancePhase 1 Terminated1 enrolled
NCT00179725 2006-04-12Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCelgenePhase 1/2 Terminated60 enrolled